Literature DB >> 3794585

Biochemical characterization of circulating Met-enkephalins in canine endotoxin shock.

J D Watson, J G Varley, S J Tomlin, S Medbak, L H Rees, C J Hinds.   

Abstract

The alterations in arterial, venous and adrenal vein levels of immunoreactive Met-enkephalins following endotoxin administration have been investigated in dogs by direct measurement and gel filtration chromatography. Animals were anaesthetized with alpha-chloralose and allowed to breath spontaneously. The left lumbar adrenal vein, limb vein and femoral artery were cannulated for blood sampling. Severe shock was produced by the administration of a large bolus of E. coli endotoxin followed by a continuous infusion. The production of endotoxin shock was associated with significant increases in adrenal vein and systemic venous plasma immunoreactive Met-enkephalin levels. Forty-five minutes after induction of endotoxin shock arterial immunoreactive Met-enkephalin levels were generally higher than baseline values. In resting anaesthetized animals a large 31,000 molecular weight form of Met-enkephalin, presumably proenkephalin, was found in plasma obtained from the adrenal vein, systemic and pulmonary circulations. Following endotoxin this enkephalin-containing peptide still predominated in arterial and venous plasma, whereas in the adrenal vein the proportion of Met-enkephalin immunoreactivity attributable to this large peptide fell. This was associated with the appearance of increasing amounts of smaller molecular forms (18,000, 8000, 3-5000 molecular weight and the pentapeptide itself). In this model enkephalin-containing peptides were not biochemically modified by their passage through the lungs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3794585     DOI: 10.1677/joe.0.1110329

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  3 in total

1.  Proenkephalin system in human polymorphonuclear cells. Production and release of a novel 1.0-kD peptide derived from synenkephalin.

Authors:  O Vindrola; M R Padrós; A Sterin-Prync; A Ase; S Finkielman; V Nahmod
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

2.  Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.

Authors:  Laura Rué; Mónica Bañez-Coronel; Jordi Creus-Muncunill; Albert Giralt; Rafael Alcalá-Vida; Gartze Mentxaka; Birgit Kagerbauer; M Teresa Zomeño-Abellán; Zeus Aranda; Veronica Venturi; Esther Pérez-Navarro; Xavier Estivill; Eulàlia Martí
Journal:  J Clin Invest       Date:  2016-10-10       Impact factor: 14.808

3.  Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction.

Authors:  Albert Giralt; Olga Carretón; Cristina Lao-Peregrin; Eduardo D Martín; Jordi Alberch
Journal:  Mol Neurodegener       Date:  2011-10-10       Impact factor: 14.195

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.